NAMS – newamsterdam pharma company n.v. - ordinary shares (US:NASDAQ)
Stock Stats
News
NewAmsterdam Pharma (NASDAQ: NAMS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $36.00 price target on the stock.
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFH [Yahoo! Finance]
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFH
Frazier Life Sciences Appoints John Smither and Jim Williams as Senior Advisors
NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024 [Yahoo! Finance]
Form 8-K NewAmsterdam Pharma Co For: Nov 20
Form 4 NewAmsterdam Pharma Co For: Nov 15 Filed by: Forbion Growth Management B.V.
Form 8-K NewAmsterdam Pharma Co For: Nov 18
Form 4 NewAmsterdam Pharma Co For: Nov 13 Filed by: Forbion Growth Management B.V.
Form SC 13D/A NewAmsterdam Pharma Co Filed by: Forbion Capital Fund IV Cooperatief U.A.
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.